Recent News

• 02.12.2025 - Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
• 02.04.2025 - Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
• 01.31.2025 - Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
• 01.31.2025 - Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
• 01.07.2025 - Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
• 12.05.2024 - Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
• 12.03.2024 - FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
• 12.03.2024 - FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Recent Filings

• 02.04.2025 - 8-K Current report
• 02.04.2025 - EX-99.1 EX-99.1
• 01.14.2025 - 8-K Current report
• 01.14.2025 - EX-99.1 EX-99.1
• 01.07.2025 - EX-99.1 EX-99.1
• 01.07.2025 - 8-K Current report
• 12.30.2024 - S-8 Securities to be offered to employees in employee benefit plans
• 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2024 - 4 Statement of changes in beneficial ownership of securities
• 12.10.2024 - 8-K Current report